6
Participants
Start Date
March 31, 2009
Primary Completion Date
November 30, 2012
Study Completion Date
November 30, 2012
testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride
"Patients will be treated with dutasteride 3.5 mg once daily (oral administration). To avoid rapid conversion of testosterone to DHT in case 5α-reductase is not adequately inhibited during the first few days of concurrent treatment with dutasteride and testosterone, daily dutasteride treatment will be initiated 7 days prior to testosterone initiation.~Patients will receive AndroGel® at the dose of 15 g (3 times the standard replacement dose for hypogonadism) once daily (topical administration), starting on Day 8 and continuing for 12 weeks (or until disease progression or withdrawal from the study)."
Memorial Sloan-Kettering Cancer Center, New York
Collaborators (1)
GlaxoSmithKline
INDUSTRY
University of Washington
OTHER
Memorial Sloan Kettering Cancer Center
OTHER